Home  /  Resource Library  /  Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single arm, multicentre, phase 2 trial

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single arm, multicentre, phase 2 trial

Results of a study investigating CAR T axicabtagene ciloleucel for treatment of relpased indolent lymphomas.